Nodular MAC Lung Disease: Treat Now or Watch the Trend
A woman newly meeting diagnostic criteria for nodular MAC pulmonary disease, with mild but new symptoms and radiographic progression. The disagreement is not about the diagnosis — it is about how much force a conditional, very-low-certainty recommendation to treat should carry in a patient who sits outside the smear-positive, cavitary disease that recommendation is explicitly weighted toward.
Diane R., a 67-year-old woman, retired eleven years ago from the middle-school library where she’d worked for three decades, and now spends most mornings walking her neighbor’s aging beagle along the same two-mile loop she’s kept for years, rain or shine, ever since her knees finally forced her to give up the jogging she used to do instead — a habit she credits, only half-joking, with keeping her out of the hospital. She was diagnosed with bronchiectasis eight years ago after a string of bronchitis episodes that never quite resolved between antibiotic courses, and has lived since then on daily airway clearance and an occasional antibiotic for flares, without ever needing anything more aggressive. Over the past four months her sputum has thickened and increased in volume, and she’s noticed a tiredness by midafternoon that wasn’t part of her routine before — nothing dramatic, no fever, no weight loss, but a real, if modest, change she brought up herself rather than waiting to be asked. Two sputum cultures four weeks apart grew Mycobacterium avium complex, and her chest CT, read against imaging from a year earlier, shows new tree-in-bud nodularity in the right middle lobe and lingula layered onto her existing bronchiectasis — together enough to meet formal diagnostic criteria for MAC pulmonary disease, not incidental colonization.
Her spirometry has barely moved — FEV1 78% of predicted a year ago, 76% now — a reading that cuts both ways: stable enough that nothing about her lung function itself argues for urgency, but new enough radiographically and microbiologically that “nothing has changed” isn’t quite true either. The 2020 ATS/ERS/ESCMID/IDSA guideline suggests initiating treatment rather than watchful waiting once diagnostic criteria are met — but it grades that as a conditional recommendation at very low certainty, and qualifies it with a phrase that does real work here: especially in the context of positive acid-fast bacilli sputum smears and/or cavitary lung disease. Her smears are negative and her CT shows no cavitation, which places her precisely outside the two features the recommendation is weighted toward, in the low-certainty margin where the same guideline directs that the decision be individualized and concedes watchful waiting is sometimes preferable. What her case turns on, then, is not whether the guideline favors treatment — it does — but how much a conditional suggestion, stripped of both qualifiers that give it force, should outweigh twelve months of ethambutol in a woman whose lung function has not moved.
Pulmonary clinic, reviewing the new cultures
Start the standard three-times-weekly regimen — azithromycin, ethambutol, rifampin — now, not after another interval of watching. Two positive cultures and new tree-in-bud nodularity superimposed on her existing bronchiectasis already meet the guideline’s diagnostic threshold, and once that threshold is met the 2020 panel’s stated suggestion is to initiate treatment rather than watch. That is the default we would be departing from, not the one we would be following, and her disease is moving, not sitting still.
Nodular/bronchiectatic MAC that later develops cavitation carries a materially worse prognosis and needs the more toxic daily regimen instead of the thrice-weekly one. Waiting to see whether she progresses risks trading a milder treatment now for a harder one later.
I’d hold off.
You’re quoting the direction of that recommendation and skipping both things that give it force. It is conditional, not strong, and the panel graded the certainty of the underlying evidence as very low — no randomized trial has shown treatment improves survival or quality of life over observation. And it is qualified: especially in the context of positive AFB smears and/or cavitary disease. Her smears are negative and there is no cavity. Strip out both qualifiers and what’s left is a very-low-certainty suggestion, against twelve or more months of ethambutol with its cumulative and occasionally irreversible optic neuropathy, rifampin’s substantial CYP3A4 induction burden, and the macrolide’s contribution to ototoxicity and QT prolongation.
If she were cavitary, or her FEV1 were actually falling, I’d be arguing the opposite position.
Neither of you is actually wrong about what the evidence says — you’re disagreeing about how to read a genuinely ambiguous trend, and that disagreement doesn’t have to be settled today by picking a side.
Repeat sputum cultures and HRCT in three months, with an explicit trigger already agreed: any new cavitation, a rise in AFB smear grade, or a real drop in FEV1 starts therapy immediately, no further discussion needed at that point. And note this is not freelancing around the guideline — the same document tells us to individualize the decision, and where treatment is deferred it asks for exactly this: an active monitoring plan rather than an open-ended one. What it will not let us do is call the deferral permanent.
Agreed: defer antibiotic initiation, repeat sputum AFB cultures and HRCT at three months, with therapy starting immediately if any of the three named triggers are met.
Not agreed, and left explicit rather than smoothed over:
All three physicians treat this as unambiguous — new cavitation or a rising AFB smear grade starts therapy the same day, no further discussion.
The pulmonologist wants symptom worsening alone to count as a trigger; the infectious disease physician thinks that threshold is too soft and would re-open the whole argument at every visit rather than resolve it.